From what 6 stock analysts predict, the share price for Corcept Therapeutics Inc (CORT) might increase by 74.65% in the next year. This is based on a 12-month average estimation for CORT. Price targets go from $23.00 to $61.00. The majority of stock analysts believe CORT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Corcept Therapeutics Inc has a total of 6 Wall St Analyst ratings. There are 5 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Corcept Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
debjit chattopadhyay Guggenheim | Sell | $7.0 | initiatedcoverage | Dec 20, 2016 |
tazeen ahmad Bank of America Securities | Sell | $5.0 | reiterated | Jun 2, 2016 |
ian somaiya BMO Capital | Sell | $1.1 | downgraded | Nov 8, 2012 |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
When did it IPO
2004
Staff Count
352
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Joseph K. Belanoff M.D.
Market Cap
$2.34B
In 2023, CORT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CORT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NMIH-USD
$29.05
BLMN-USD
$26.6
JBLU-USD
$7.01
$73.03
APPN-USD
$32.98
PLUG-USD
$3.96